Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Less Is More: FDAMA Implementation Veteran Will Guide User Fee Program

This article was originally published in The Gray Sheet

Executive Summary

Office of Device Evaluation IDE/HDE Programs Director Joanne Less will help supervise implementation of the Center for Devices & Radiological Health's user fee program

You may also be interested in...



FDA Veteran Schultz Ascends To CDRH Director Position: Who Will Lead ODE?

CDRH's new director, Daniel Schultz, MD, says he would be open to hiring an Office of Device Evaluation chief who lacks a medical degree

FDA Veteran Schultz Ascends To CDRH Director Position: Who Will Lead ODE?

CDRH's new director, Daniel Schultz, MD, says he would be open to hiring an Office of Device Evaluation chief who lacks a medical degree

User Fee Funds Will Not Be Confined To Premarket Review Activities – Feigal

Device user fees will be allocated toward activities other than premarket review as CDRH struggles to compensate for fiscal 2003 appropriation shortfalls

Related Content

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel